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Abstract
The main indicators of quality of life in patients with chronic hepatitis C with concomitant diabetes mellitus type II were studied
on the basis of SF-36. A sharp decrease in physical and mental health was observed in patients with combined comorbidity
in comparison with the group of patients without concomitant diabetes mellitus type II. Improvement of the patients’ quality of
life by all parameters was detected under the influence of alpha-lipoic acid and lactulose use in addition to antiviral therapy.
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Problem statement and analysis of the
recent research
The issue of viral hepatitis (VH) is one of the most urgent
and unresolved issues in medical science and health care [1,
7, 8]. This is evidenced by the rapid spreading, more fre-
quent monitoring of this pathology in young patients, high
risk of hepatic cirrhosis (HC) and hepatocellular carcinoma
development. Studies of recent decades have shown that HCV
infection is not only a cause of hepatic disorders but is also
a systemic pathological process, generalized infection result-
ing in many organs and systems affection [2, 3, 7]. Unlike
hepatitis B, hepatitis C incidence is associated with increased
incidence of diabetes mellitus (DM) type II: there is some link
(or links) between the presence of hepatitis C virus and the
onset of DM type II. Hepatitis C virus (HCV) (in particular,
genotypes 3a and lb) in the body is known to increase cells
insulin resistance directly interfering with insulin-signaling
cascade [5, 10, 11]. Insulinemia in its turn leads to increased
replication of HCV in vitro [12]. The study of the mecha-
nisms of both liver and body as a whole damage in case of
this associated pathology is an extremely important aspect of
modern medicine. Chronic diseases in patients manifest not
only in significant expenditure but also in the negative impact
on lifestyle [2, 9]. Therefore, it is important for the doctor
to determine how the disease affects the person, including all
aspects of life. These types of studies focused directly on a
patient are known as the study of quality of life (QOL).
Quality of life (QOL) is a concept encompassing many
aspects of human life and describes the ability of an individual
to function in a society according to his or her status and
to enjoy it. Over the last years the study of health related
quality of life (HRQL) has developed as a separate medical
science with its research methods, evaluation criteria, domain
of usage, etc. It is based on the definition of QOL by the WHO
as individual correlation of the position in the community in
the context of culture and value system of the society with
the goals of the individual, his or her plans, abilities and the
degree of general unsettled state [6, 9], that is the person’s
perception of his or her position in life including physical,
mental and social well-being, independence, quality of the
environment where he or she lives, the degree of satisfaction.
Indicator of QOL related to health generally reflects the degree
of person’s adaptation to the disease and ability to perform
usual functions corresponding to the socio-economic status
[6, 9].
The study of 642 patients with chronic hepatitis C (CHC)
confirmed that individuals with hepatitis C had lower quality
of life than the control group [4, 6]. In addition, patients with
a sustained response to monotherapy with interferon were
found to experience a significant improvement in quality of
life. Evaluating the quality of life of patients with CHC with-
out cirrhosis before the treatment Foster and colleagues [13]
found that patients with CHC had significantly lower quality
of life in all eight areas of SF-36. Even if clinical signs of
liver damage are absent, the very presence of HCV infection
or even just the patient’s awareness on his disease decreases
the quality of life due to both its physical and mental compo-
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nent. According to the meta-analysis of 15 studies of QOL
with the use of SF-36, decrease in QOL by 9 -20 points on
average was observed in patients with CHC compared to the
healthy control group [4]. The mere fact of CHC diagnosis
may influence QOL. SF-36 indicators in one of the researches
were significantly lower among the patients with CHC who
knew about their disease in comparison with those who did
not know about their CHC. This indicates the strong psycho-
logical impact of the mere fact that the patient suffers from
this disease [6, 9]. Therefore, we consider the study of QOL
of patients with CHC, especially with comorbidity, and the
impact of treatment on quality of life to be advisable.
The objective of the research was to study the dynamics
of the main indicators of quality of life of patients with CHC
and concomitant DM type II under the influence of treatment.
1. Materials and methods
104 patients with CHC (84 patients with CHC associated with
DM type II and 20 patients without comorbidity as a com-
parison group) at the age of 21 to 65 were included into the
research. They underwent examination, treatment and obser-
vation at the clinical base of the Department of Infectious
Diseases at Ivano-Frankivsk National Medical University in
the Department #1 at the Regional Clinical Infectious Dis-
eases Hospital in Ivano-Frankivsk. The patients were divided
as follows: 84 patients with CHC on the background of con-
comitant DM type II were treated with antiviral therapy (AVT)
with pegylated interferon alpha-2b and alpha-2a and ribavirin
during 48 weeks. These patients were divided into 4 groups
depending on the treatment. 20 patients (Group I) received
only AVT. 21 patients (Group II) received alpha lipoic acid
(ALA) in addition to AVT. 23 patients (Group III) received
lactulose in addition to AVT. 20 patients (Group IV) received
ALA and lactulose according to the proposed regimen along
with AVT. All patients were with genotype 1b.
Russian version of the international SF-36 questionnaire
was used to determine the QOL indicators. This version was
developed by the researchers at the International Center for
Quality of Life Studies, (ICQLS, Saint-Petersburg, 1998).
The results of the research showed its high consistency with
the QOL characteristics conducted in other countries. Thus,
Ukraine has the experience in adaptation of the international
version of SF-36 questionnaire which may be used to study
the QOL of healthy individuals of all categories of patients,
to evaluate the effectiveness of comprehensive treatment or
individual drug action. The use of SF-36 questionnaire pro-
vides an opportunity to obtain integrated quantitative evalua-
tion of QOL of patients with CHC and completes conducted
comprehensive researches. In order to measure QOL the SF-
36 questionnaire determined the following criteria: Physical
Functioning (PF), Role-Physical Functioning (RP), Bodily
Pain (BP) and its impact on the ability to be engaged in daily
activities, General Health (GH) as a subjective respondent’s
assessment of his general health at the present time, Vitality
(VT) as a subjective respondent’s assessment of his vitality,
Social Functioning (SF), the role of emotional problems in
physical dysfunction (Role-Emotional – RE), Mental Health
(MH) as a subjective mood assessment.
QOL criteria are used to determine the effectiveness of
treatment in health programs, to determine the benefits of
treatment approach [6, 9].
Questionnaires were formed to determine the quality of
life. They were completed by patients before the treatment,
after 2 and 6 months of the treatment and at the end of the
therapy.
All patients were included into the research after signing
an informed consent.
Statistical processing of the research results was con-
ducted on a PC using a standard package Statistica 5. Mean
values (M), mean error (m), significance of differences ac-
cording to Student’s t-test were assessed. Pearson correlation
coefficient was used to assess interrelation between the studied
characteristics.
2. Results of the research and their
discussion
Studying the effect of DM type II on the quality of life of
patients with CHC before the treatment, we detected the fol-
lowing changes in the main indicators of SF-36 questionnaire
(Table 1). PF indicator in the patients with concomitant DM
type II was 1.3 times lower than in patients with CHC with-
out comorbidities (53.27±1.91 versus 71.25±3.42, p<0.001)
and 1.6 times lower than in the control group (p<0.001). PF
indicator in patients with CHC without comorbidity was 1.2
times lower than in healthy individuals (p>0.05).
Physical abilities restriction led to the decrease in everyday
activity of patients in both groups according to PF indicator.
However, PF indicator in patients of the comparison group
was not significantly different from that in the control group
(51.25±9.15 points versus 65.9±5.54, p>0.05).
PF indicator in patients with concomitant DM type II
constituted 27.81 ± 4.27 scores and was 1.8 times lower
than in the comparison group (p<0.001) and 2.4 times lower
compared to the control group (p<0.01) (see Table 1).
Pain syndrome in terms of BP indicator was not signifi-
cantly different compared to the control in both studied groups
(p>0.05) but was 1.3 times lower in the main group com-
pared to the comparison group (p<0.001). The overall assess-
ment of patients’ health as satisfactory was decreased in both
groups in comparison with healthy individuals and constituted
47.70±3.85 scores in the patients without concomitant DM
type II and 37.40±2.37 scores in the patients of the main
group (p<0.001). Moreover, GH index was 1.3 times lower
in the main group than in the comparison group (p<0.05).
VT indicator decreased in both groups with no significant
difference between the groups (p>0.05). Social activity of
patients with CHC and concomitant DM type II (according to
SF indicator) decreased by 1.3 times in comparison with the
control group and comparison group (p<0.001, p<0.05) due
to the presence of more significant clinical symptoms (general
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Table 1. Indicators of quality of life in patients with CHC and concomitant diabetes mellitus type II before the treatment,
M±m
Indicators Apparently healthy
individuals (n=20)
CHC without DM type
II (n=20)
CHC with concomitant
DM type II (n=84)
p p1 p2
PF 83.8±6.17 71.25±3.42 53.27±1.91 >0.05 <0.001 <0.001
RF 65.9±5.54 51.25±9.15 27.81±4.27 >0.05 <0.001 <0.05
BP 62.2±5.03 70.40±5.98 53.55±2.49 >0.05 >0.05 <0.01
GH 73.2±5.82 47.70±3.85 37.40±2.37 <0.001 <0.001 <0.05
VT 68.0±4.96 38.75±5.19 31.52±2.27 <0.001 <0.001 >0.05
SF 69.9±4.68 65.38±5.23 52.23±2.35 >0.05 <0.01 <0.05
RE 51.4±4.49 69.98±7.22 23.90±3.33 <0.05 <0.001 <0.001
MH 60.4±3.86 54.20±3.04 45.02±1.97 >0.05 <0.001 <0.01
Notes.
p – significant between the healthy individuals and the patients with chronic hepatitis C without comorbidities;
p1 – significant between the healthy individuals and the patients with chronic hepatitis C with concomitant diabetes mellitus type II;
p2 – significant between the patients with chronic hepatitis C without comorbidities and the patients with chronic hepatitis C with
concomitant diabetes mellitus type II.
weakness, fatigability, nausea, discomfort and pain in the right
hypochondrium). Social activity of the patients in the com-
parison group did not decrease and constituted 65.38±5.23
scores compared to 69.9±4.68 points in the control group
(p>0.05).
Patients of both study groups had significantly lower in-
dices of mental status. Restriction of daily activities due to
emotional problems was more significant in patients with
CHC combined with DM type II – RE indicator was 2.9
times lower than in patients without comorbidity (23.90±3.33
scores versus 69.98±7.22 scores, p<0.001) and 2.2 times
lower than in healthy individuals (p<0.001). RE indicator in
the patients of comparison group was almost identical to that
in healthy individuals. “Mental health” (MH) indicator was
reduced by 1.12 times (p<0.05) in patients with CHC without
DM II and did not differ from the data of healthy individuals
(p<0.05) while MH indicator in the patients of the main group
decreased by 1.3 times in comparison with the control group
(p<0.001) and 1.2 times compared to the comparison group
(p<0.05).
Thus, the presence of associated CHC pathology and DM
type II significantly reduces the quality of life of patients
and the planned prescription of antiviral therapy (AVT) also
reduces the emotional and mental part of patients’ normal so-
cial activity and directly affects the physical health sensation.
Therefore, the use of medication contributing to the mainte-
nance of normal physical and mental functioning of patients
with CHC with concomitant diabetes type II, namely α-lipoic
acid and lactulose is reasonable.
The influence of the proposed treatment regimen on the
quality of life of the patients is shown in Table 2. Normaliza-
tion of quality of life 2 months after the beginning of treatment
in the patients of group I who underwent only AVT occurred
only according to 1 criterion (BP) which approximated to
the indicator of the control group (59.60±1.57 scores versus
53.35±4.99 scores and 62.20±5.03 scores, p>0.05).
6 months after the beginning of treatment in this group,
normalization of quality of life occurred in terms of 4 indi-
cators of SF-36 questionnaire: RE indicator increased by 2.5
times, BP indicator increased by 1.1 times, SF indicator in-
creased by 1.5 times and MH indicator increased by 1.3 times.
At the end of treatment another indicator, namely RF (p>0.05)
returned to normal. That is, the use of AVT helped to reduce
the patients’ perception of their health as such that limited
ordinary physical activity, patients’ social activity, reduced
the intensity of pain. Deterioration of the mental health com-
ponent (due to worsening of mood, the constant presence of
anxiety and improved patients’ mental health) and patients’
physical activity was detected in this group within 2 months
of treatment with AVT. The improvement in this indicator
occurred after 6 months of treatment.
Normalization of quality of life occurred after 2 months of
treatment in terms of 2 indicators (SF, BP, p>0.05) in patients
of group II who were treated with alpha-lipoic acid on the
background of AVT. SF indicator increased by 1.3 times after
6 months of treatment in comparison with that before the treat-
ment, RE indicator increased by 2.06 times (p<0.001) and
MH indicator increased by 1.2 times (p<0.001). Improvement
in QOL in terms of already 5 indicator of SF-36 questionnaire
(RF, BP, SF, RE and MH) (p>0.05) was detected at the end
of treatment in patients of group II. Thus, the use of ALA
along with AVT promoted the decrease in the sense of impact
of physical and emotional problems on restriction of daily
activities.
Analyzing the dynamics of the quality of life indicators
in the patients of group III who were prescribed lactulose
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Table 2. Dynamics of quality of life indicators in the patients with CHC and concomitant diabetes mellitus type II under the
influence of treatment, M±m
Study groups PF RF BP GH VT SF RE MH
Healthy (n=20) 83.8±6.17 65.9±5.54 62.2±5.03 73.2±5.82 68.0±4.96 69.9±4.69 51.4±4.49 60.4±3.86
I
Before the treat-
ment (n=20)
48.75±1.66 25.00±8.89 53.35±4.99 36.50±4.70 31.15±5.38 52.50±4.01 24.98±6.34 44.80±4.05
2 months of
treatment
36.00±1.69
*#@
15.00±2.81
#@
59.60±1.57
@
33.33±1.72
#@
33.00±1.38
#@
50.63±0.63
#@
34.97±1.67
#@
36.00±0.82
***@
6 months of
treatment
65.50±1.49
*##
62.50±2.87
*
58.30±3.29
@
54.50±0.57
*##
56.50±1.54
*###
77.25±3.27
*
64.94±1.67
*##
58.80±1.23
*
12 months of
treatment
55.50±5.27
##@@@
57.50±6.81
**@@@
69.40±4.69
***@@@
54.90±3.31
**##
52.00±3.49
*###
73.75±3.94
*@@@
53.31±7.01
*@
58.80±2.50
**
II
Before the treat-
ment (n=21)
55.95±5.57 26.19±7.21 53.43±6.57 38.48±4.46 31.95±4.42 51.79±3.48 23.79±5.70 44.19±3.54
2 months of
treatment
60.71±3.85
##@@@
40.48±7.61
##@
68.86±4.58
@
49.10±3.25
***##@
45.48±2.95
***#@
67.26±3.81
**@
42.81±3.36
**#
49.78±3.00
###@@
6 months of
treatment
58.33±3.91
##
44.05±6.43
###@@@
81.43±2.63
*#@
51.52±1.82
**##
45.48±1.98
**#@@@
70.39±2.86
*@@@
49.17±5.45
*@@
53.90±3.14
***@@@
12 months of
treatment
62.62±3.44
##
64.29±5.05
*
70.14±5.80
@@@
44.14±5.14
#@@
41.90±4.86
#@@@
66.67±6.30
***@@@
61.09±9.91
*@
48.76±4.42
@@@
III
Before the treat-
ment (n=22)
56.52±3.92 26.09±9.36 54.00±4.17 36.65±4.39 31.13±4.43 51.14±5.26, 23.17±6.77 45.22±4.29
2 months of
treatment
33.91±0.44
*#@
20.65±2.02
#@
61.65±1.65
@
33.70±1.81
#@
34.57±1.47
#@
50.54±0.54
#@
34.89±1.59
#@
36.52±0.77
#@
6 months of
treatment
66.74±1.46
***###
64.13±2.64
*
64.13±2.64
***@@@
74.17±4.88
*@@
54.17±0.53
*###
75.87±3.46
*
65.15±1.45
*#
60.87±1.22
**
12 months of
treatment
58.04±5.05
##@@@
58.70±6.21
*@@@
71.30±4.55
**@@@
56.48±3.05
*###
53.70±3.34
*###
73.91±3.68
*@@@
56.50±6.77
**@
59.48±2.24
**
IV
Before the treat-
ment (n=20)
51.25±2.05 25.00±8.89 53.35±4.61 38.05±5.79 31.90±4.18 51.25±5.66 23.32±8.41 44.00±4.21
2 months of
treatment
72.00±1.38
***
75.00±4.44 98.50±1.50
*#
62.00±1.03
*
58.00±0.92
*
85.00±1.15
*##
59.94±3.06
*
58.40±1.10
**
6 months of
treatment
66.25±3.48
###
63.75±7.13 93.50±2.58
*#
56.25±2.10
**##
53.50±2.33
*###
81.88±3.57
*
71.64±6.06
*###
64.00±3.31
*
12 months of
treatment
73.50±4.20
***
77.50±5.71 86.35±4.66
*##
66.10±5.18
**
58.25±5.56
*
89.29±5.69
*###
96.66±2.30
*#
63.60±5.18
**
Notes.
p<0.001*; p<0.01**; p<0.05*** – a significant difference between the indicator before the treatment of patients with CHC and
concomitant DM and the indicator in each study group after the treatment;
p<0.001#; p<0.01##; p<0.05### – significant difference between the indicator in each study group after the treatment and healthy
individuals;
p<0.001@; p<0.01@@; p<0.05@@@ – significant difference between the indicator in each study group after the treatment and the same
indicators in the patients of Group I.
in addition to AVT, the positive tendency towards QOL nor-
malization was observed only after 6 months of treatment.
At the end of the treatment QOL normalization in group III
occurred in terms of 5 indicatora of SF-36 questionnaire (RF,
BP, SF, RE and MH) that increased by 2.4 times in terms of
RF, (p<0.001), by 1.3 times in terms of BP, (p<0.05), by 1.4
times in terms of SF, (p<0.001), by 2.4 times in terms of RE,
(p<0.001) and by 1.3 times in terms of MH, (p<0.01). In
addition, a decrease in mental health indicator (MH) and phys-
ical activity indicator (RF) (p<0.001) was observed in this
group of patients after 2 months of treatment in comparison
with the indicators before the treatment. This may indicate
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negative reaction to AVT in these patients.
Using ALA and lactulose along with AVT in group IV,
the normalization of QOL of patients in terms of all SF-36
questionnaire indicators was observed during the observation
period with a significant difference between the groups (see
Table 2). At the end of treatment PF indicator in this group of
patients was 1.3 times higher than in groups I and III (p<0.05),
1.2 times than in group II (p>0.05). RF indicator in patients
of group IV was 1.3 times higher than in groups I and III
(p<0.05). Pain indicator BP was higher in patients of group
IV compared to groups I, II, and III by 1.2 times on average
at the end of treatment (p<0.05). GH indicator in the patients
of group IV was 1.4 times higher in comparison with group
II (p<0.01). VT indicator in group IV increased by 1.4 times
(p<0.05). Social activity (SF) of the patients in group IV
was 1.2 times higher compared to study groups I and III and
1.3 times higher in comparison with group II (p<0.05). RE
indicator in the patients of group IV was 1.9 times higher
than in group I (p<0.001), 1.6 times higher than in group II
(p<0.001) and 1.8 higher than in group III (p<0.001). MH
indicator in the patients of group IV was 1.1 times higher
compared to study groups I and III and 1.3 times higher than
in group II.
Summarizing, a conclusion may be drawn that conducted
therapy significantly improved both the physical condition
and mental status of the patients. Moreover, the conducted
research demonstrated significant improvement of QOL in pa-
tients treated with comprehensive therapy with the inclusion
of alpha-lipoic acid and lactulose, with almost complete phys-
ical and social rehabilitation during the period of treatment.
3. Conclusions
1. The results of QOL analysis using SF-36 questionnaire
demonstrated that a sharp decrease in all QOL indica-
tors was observed patients with CHC and concomitant
DM type II.
2. Normalization of quality of life in patients of group I
after AVT occurred according to 4 indicators of SF-36
questionnaire (RE, BP, SF and MH). Normalization
of quality of life in patients of group II and III who
received AVT in complex with alpha-lipoic acid and
lactulose occurred according to 5 indicators of SF-36
questionnaire (RF, BP, SF, RE and MH). The normal-
ization of QOL according to all indicators of SF-36
questionnaire was observed throughout the observation
period and the significant difference between the groups
in patients of group IV who were treated with AVT in
combination with alpha-lipoic acid and lactulose.
3. The inclusion of assessment of patients’ quality of life
according to SF-36 questionnaire is important to as-
sess the severity of chronic hepatitis C and treatment
efficacy.
4. Prospects for further research
The research is promising in terms of further study of QOL
in patients with CHC with the use of new direct-acting antivi-
ral drugs and their combined use with alpha-lipoic acid and
lactulose.
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